Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Pignata

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancerM C Piccirillo, G Scambia, A Bologna, et al.
ESMO Open|May 20, 2025
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparibL Beltrame, L Mannarino, A Sergi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2024
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapyS Pignata, D Califano, D Lorusso, et al.
ESMO Open|November 19, 2025
PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric surveyM Turinetto, C Marchetti, G Scandurra, et al.
ESMO Open|September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trialE D Capoluongo, B Pellegrino, L Arenare, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2023
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trialI Ray-Coquard, A Leary, S Pignata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Dostarlimab and niraparib in primary advanced ovarian cancerA-C Hardy-Bessard, E Pujade-Lauraine, R G Moore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2024
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseJ A Ledermann, X Matias-Guiu, F Amant, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancerM C Piccirillo, G Scambia, A Bologna, et al.
ESMO Open|May 20, 2025
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparibL Beltrame, L Mannarino, A Sergi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2024
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapyS Pignata, D Califano, D Lorusso, et al.
ESMO Open|November 19, 2025
PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric surveyM Turinetto, C Marchetti, G Scandurra, et al.
ESMO Open|September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trialE D Capoluongo, B Pellegrino, L Arenare, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2023
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trialI Ray-Coquard, A Leary, S Pignata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Dostarlimab and niraparib in primary advanced ovarian cancerA-C Hardy-Bessard, E Pujade-Lauraine, R G Moore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2024
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseJ A Ledermann, X Matias-Guiu, F Amant, et al.
Pageof 12